explore -WSS

explore

author：explore 2025-09-02 22:24:23 - browse：5243

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Phenylephrine and the overlooked value of the placebo effect

knowledge

hotspot

WSS

Dogs on Prozac: What pet anti

Bill would stop addiction treatment from triggering child abuse inquiry

Why age limits for politicians are a terrible idea

Why does health care cost so much? A reading guide

The future of health care in the House

Bill would stop addiction treatment from triggering child abuse inquiry

Wikipedia

explore

knowledge

Sports medicine is finally prioritizing gender equality

Bristol 'take

Alkermes shareholders re

Sana to lay off nearly a third of staff, de

Medicare proposal to cover medical devices draws a mixed reaction

Stroke deaths set to near 10 million globally by 2050

Alkermes shareholders re

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

How one medical school became remarkably diverse

FDA authorizes Novavax’s updated Covid

entertainment

Key Senate committee drafts bipartisan bill to stem drug shortages

FDA authorizes Novavax’s updated Covid

Why Charlie Gard's case is so disturbing to Americans

FDA panel signals lack of confidence in Amgen cancer drug data

FTC falls short on scrutinizing hospital mergers, study says

H5N1 bird flu found in pasteurized milk: what we know

knowledge

knowledge

hotspot

knowledge